Quick Answer
Centessa Pharmaceuticals plc reported Cash And Cash Equivalents At Carrying Value of $61.30 million for the year ending 2025.
- Centessa Pharmaceuticals plc showed a decrease of -84.0% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Centessa Pharmaceuticals plc's annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $613.76 million | Q3 2021: $578.82 million | Q1 2022: $544.47 million | Q2 2022: $484.16 million | Q3 2022: $444.84 million | Q1 2023: $259.99 million | Q2 2023: $145.22 million | Q3 2023: $171.50 million | Q1 2024: $118.22 million | Q2 2024: $127.37 million | Q3 2024: $395.03 million | Q1 2025: $105.16 million | Q2 2025: $44.24 million | Q3 2025: $50.81 million.
- Over the full 6 years of available data (2020 to 2025), Centessa Pharmaceuticals plc's Cash And Cash Equivalents At Carrying Value has grown by 748.2%.
- Historical annual values: Fiscal year 2025: $61.30 million | Fiscal year 2024: $383.22 million | Fiscal year 2023: $128.03 million | Fiscal year 2022: $393.64 million | Fiscal year 2021: $595.08 million | Fiscal year 2020: $7.23 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: